Importance Direct oral anticoagulants (DOACs), comprising apixaban, rivaroxaban,
edoxaban, and dabigatran, are commonly used medications to treat patients with atrial …

Clinical prediction of underlying pathologic substrates in people with Alzheimer's disease
(AD) dementia or related dementia syndromes (ADRD) has limited accuracy. Etiologic …

Importance Extending the duration of oral anticoagulation for venous thromboembolism
(VTE) beyond the initial 3 to 6 months of treatment is often recommended, but it is not clear …

Background Clinical trials suggest lower rates of major bleeding with direct-acting oral
anticoagulants (DOACs) than with warfarin, but anticoagulant-related bleeding remains one …

Importance The influence of race and ethnicity on initiation of direct oral anticoagulants
(DOACs) is relatively understudied in Medicare data. Objective To investigate disparities in …

Abstract Background In 2011, the American Academy of Orthopaedic Surgeons released a
consensus recommending venous thromboembolism (VTE) prophylaxis after total knee …

Abstract Background Direct oral anticoagulants (DOACs) are increasingly prescribed for the
prevention and treatment of thrombosis. However, DOACs are associated with extensive …

Aim Non-vitamin K antagonist oral anticoagulants (NOACs) were developed as an
alternative to warfarin to prevent thromboembolism in patients with atrial fibrillation (AF) …

Background Use of direct oral anticoagulants (DOACs) in patients with cancer remains
suboptimal due to the concern regarding potential drug-drug interactions (DDIs) with …

Objective To assess the cost-effectiveness of pharmacogenomics (PGx)-based warfarin (ie,
warfarin dosing following genetic testing), apixaban, and rivaroxaban oral anticoagulation …